Hyperlipidaemia in primary biliary cholangitis: treatment, safety and efficacy. Issue 4 (9th January 2019)

• Record Type: Journal Article
• Authors: Wah-Suarez, Martin I; Danford, Christopher J; Patwardhan, Vilas R; Jiang, Z Gordon; Bonder, Alan
• Is Part Of: Frontline gastroenterology. Volume 10:Issue 4(2019)
• Page Start: 401
• Page End: 408
• Publication Date: 2019-01-09
• Subjects: cardiovascular disease -- primary biliary cirrhosis; Gastroenterology -- Periodicals; 616.33005
• DOI: 10.1136/flgastro-2018-101124
• Languages: English
• ISSNs: 2041-4137

Abstract

Abstract : Primary biliary cholangitis (PBC) is an autoimmune liver disease associated with altered lipoprotein metabolism, mainly cholesterol. Hypercholesterolaemia, a major modifiable risk factor for cardiovascular disease in the general population, occurs in 75%–95% of individuals with PBC. The impact of hypercholesterolaemia on cardiovascular risk in PBC, however, is controversial. Previous data have shown that hypercholesterolaemia in PBC is not always associated with an increase in cardiovascular events. However, patients with PBC with cardiovascular risk factors may still warrant cholesterol-lowering therapy. Treatment of hypercholesterolaemia in PBC poses unique challenges among primary care providers due to concerns of hepatotoxicity associated with cholesterol-lowering medications. This review summarises the current understanding of the pathophysiology of hypercholesterolaemia in PBC and its pertinent cardiovascular risk. We will also discuss indications for treatment and the efficacy and safety of available agents for hypercholesterolaemia in PBC.